“Optimizing the treatment sequence: the cumulative clinical benefit of treatment initiation with deucravacitinib versus apremilast over 52 weeks in patients with moderate to severe plaque psoriasis from the POETYK PSO-1 trial” (2022) SKIN The Journal of Cutaneous Medicine, 6(6), p. s62. doi:10.25251/skin.6.supp.62.